(function(){var loadHandler=window['sl_{DC1F7540-1882-43D0-A075-6AAB30A2CE8C}'];loadHandler&&loadHandler(2, '<div id="spr0_5dc055a1"><div id="spr1_5dc055a1" class="kern slide"><img id="img4_5dc055a1" src="data/img1.png" width="720px" height="540px" alt="" style="left:0px;top:0px;"/></div><div id="spr2_5dc055a1" class="kern slide"><img id="img0_5dc055a1" src="data/img2.png" width="721.48" height="100.8" alt="" style="left:-1.48px;"/><div id="svg1_5dc055a1" style="left:-1.48px;top:99.523px;"><svg width="722" height="4" viewBox="0 0 722 4"><path fill="#c76c02" d="M0,0 h721.48 v3.6 h-721.48 Z"/></svg></div><div id="svg2_5dc055a1" style="left:-1.48px;top:0.523px;"><svg width="722" height="4" viewBox="0 0 722 4"><path fill="#2e3546" d="M0,0 h721.48 v3.6 h-721.48 Z"/></svg></div><img id="img1_5dc055a1" src="data/img3.png" width="721.48" height="43.101" alt="" style="top:496.899px;"/><div id="spr3_5dc055a1" style="left:657.715px;top:499.855px;"><img id="img2_5dc055a1" src="data/img4.png" width="56" height="36" alt="CHRC logo_with text.psd" style="left:-0.105px;top:-0.177px;"/></div><div id="spr4_5dc055a1" style="left:-0.12px;top:6.606px;"><div style="width:0px;"><span id="txt0_5dc055a1" data-width="114.808594" style="left:302.562px;top:4.715px;">IMPROVE-IT</span></div><div style="width:0px;"><span id="txt1_5dc055a1" data-width="470.285156" style="left:124.857px;top:33.515px;">Ezetimibe Add-on to Simvastatin was Beneficial in</span></div><div style="width:0px;"><span id="txt2_5dc055a1" data-width="297.468750" style="left:211.357px;top:62.315px;">Persons with ACS and Diabetes</span></div></div><div id="spr5_5dc055a1" style="left:13.757px;top:504.073px;"><div style="width:0px;"><span id="txt3_5dc055a1" class="nokern" data-width="218.658691" style="left:7.2px;top:-1.329px;">CV, cardiovascular; MI, myocardial infarction; UA, unstable angina.</span></div><div style="width:0px;"><span id="txt4_5dc055a1" class="nokern" data-width="620.775879" style="left:7.2px;top:9.471px;">Giguliano RP et al. Benefit of adding ezetimibe to statin therapy on cardiovascular outcomes and safety in patients with vs without diabetes: the IMPROVE-IT trial.. Presented at the European</span></div><div style="width:0px;"><span id="txt5_5dc055a1" class="nokern" data-width="223.215820" style="left:7.2px;top:20.271px;">Society of Cardiology Congress; August 30, 2015; London, England.</span></div></div><div id="spr6_5dc055a1" style="left:50.26px;top:115.451px;"><img id="img3_5dc055a1" src="data/img6.png" width="618" height="369" alt="A screenshot of a map  Description automatically generated" style="top:0.06px;"/></div></div></div>');})();